• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Climb Bio, Inc. - Common Stock (NQ:CLYM)

14.00 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Climb Bio, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 06, 2026
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
June 11, 2026
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
June 05, 2026
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
May 26, 2026
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect ↗
May 21, 2026
Climb Bio (NASDAQ:CLYM) outlined its clinical development strategy and upcoming data readouts during a fireside chat at H.C. Wainwright’s BioConnect Conference, with management emphasizing two biologic... 
Via MarketBeat
News headline image
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
May 14, 2026
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present at Upcoming Investor Conferences
May 12, 2026
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
May 07, 2026
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts
May 05, 2026
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio, Inc. Announces $110.0 Million Private Placement
April 28, 2026
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
April 07, 2026
Global Phase 2 open-label clinical trial in pMN (PrisMN) enrolling, with initial data anticipated H2 2026 
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 05, 2026
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present at Upcoming Investor Conferences
February 05, 2026
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026
January 08, 2026
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Unusual volume stocks in Tuesday's session ↗
December 16, 2025
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Which stocks are moving on Monday? ↗
December 15, 2025
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Monday's session: top gainers and losers ↗
December 15, 2025
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
December 12, 2025
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 25, 2025
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 06, 2025
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present at Upcoming Investor Conferences
November 03, 2025
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy
October 21, 2025
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
October 20, 2025
 
Via Benzinga
News headline image
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025
October 17, 2025
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity ↗
October 16, 2025
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline. 
Via Benzinga
News headline image
This Celestica Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
October 16, 2025
 
Via Benzinga
News headline image
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
October 01, 2025
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
September 29, 2025
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025
September 04, 2025
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences
August 25, 2025
From Climb Bio, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap